RT Journal Article
SR Electronic
T1 Nitric oxide gas inhalation to prevent COVID-2019 in healthcare providers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.05.20054544
DO 10.1101/2020.04.05.20054544
A1 Gianni, Stefano
A1 Fakhr, Bijan Safaee
A1 Araujo Morais, Caio Cesar
A1 Fenza, Raffaele Di
A1 Larson, Grant
A1 Pinciroli, Riccardo
A1 Houle, Timothy
A1 Mueller, Ariel Louise
A1 Bellavia, Andrea
A1 Kacmarek, Robert
A1 Carroll, Ryan
A1 Berra, Lorenzo
YR 2020
UL http://medrxiv.org/content/early/2020/04/11/2020.04.05.20054544.abstract
AB Introduction In human hosts, SARS-CoV-2 causes a respiratory syndrome (named COVID-19) which can range from a mild involvement of the upper airways to a severe pneumonia with acute respiratory syndrome that requires mechanical ventilation in an intensive care unit (ICU). Hospital-associated transmission is an important route of spreading for the SARS-CoV-2 virus and healthcare providers are at the highest risk. As of February 2020, 1716, Chinese healthcare workers had confirmed SARS-CoV-2 infections and at least 6 died. Unfortunately, there is currently no vaccine or pharmacological prophylaxis to decrease the risk of healthcare providers contracting the infection.Methods and analysis We will randomize 470 healthcare providers scheduled to work with COVID 19 patients to receive nitric oxide gas administration (NO group, n=235) or no gas administration (control group, n=235). The primary endpoint of this study is the incidence of subjects with COVID-19 disease at 14 days from enrollment. Secondary endpoints are the proportion of healthcare providers who present a positive real time RT-PCR test for SARS-CoV- 2 14 days after enrollment, the proportion of healthcare providers requiring quarantine, and the total number of quarantine days in the two groups.Ethics and dissemination The trial protocol is under the approval of The Partners Human Research Committee of Massachusetts General Hospital (Boston, USA) and recruitment is expected to start in April 2020. The results of this study will be published in scientific journals and presented at scientific meetings.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04312243Funding StatementLocal departmental funds Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sharing not applicable to this article as no datasets were generated or analysed during the current study.